Trial Profile
Adalimumab (Humira) as add-on therapy in the treatment of patients with severe persistent therapy resistant asthma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 05 Nov 2022 Status changed from completed to discontinued.
- 26 Sep 2022 Status changed from recruiting to completed.
- 26 May 2011 New trial record